fbpx

News:  Plus Therapeutics Presents Data from Preclinical Study of 186RNL in LM & Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial

Leptomeningeal Metastases:
U.S. Phase 1 Clinical Trial

 

Not Yet Recruiting

Leptomeningeal
Metastases:
U.S. Phase 1 Clinical Trial

 

Not Yet Recruiting

Leptomeningeal
Metastases:
U.S. Phase
1 Clinical
Trial

 

Not Yet Recruiting

Trial Information

Leptomeningeal metastases (LM) are a rare but typically fatal complication of advanced cancer affecting the fluid-lined or intrathecal structures of the central nervous system.  Despite affecting over 110,000 people annually in the U.S., highly effective, approved treatments are not available.

Plus Therapeutics is developing the 186RNL radiotherapeutic for the treatment of breast and non-small cell lung cancer patients with LM after standard surgical, radiation, and/or chemotherapy treatment.  The ReSPECT™-LM (Leptomeningeal Metasases) U.S. Phase 1 Clinical Trial is planned to initiate in late 2021.

View Trial on ClinicalTrials.gov

NATIONAL TRIAL REFERENCE NUMBER

NCT05034497

When speaking with your physician, please have the national trial reference number available.

Patients Treated to Date

Single Group

  • All patients who enroll in the trial will receive medication while on the study.
  • All patients will receive a single dose of Rhenium-186 NanoLiposome (186RNL).

Phase 1

  • A Phase 1 study of a new medication is usually the first that involves human volunteers who have the disease or condition the investigational medicine is designed to treat.  The primary objective of Phase 1 studies is to identify the highest dose of the new medication that can be safely given without serious side effects.

Progress

  • Actual Study Start:  by end of 2021
  • Estimated Primary Completion:  to be determined (the date that the last participant in a clinical study was examined or received an intervention and that data for the primary outcome measure were collected)
  • Estimated Study Completion:  to be determined (the date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events, that is, the last participant’s last visit). 

Patient Eligibility

Only a qualified healthcare professional can determine whether or not you are eligible to participate in a clinical trial. However, this information may be beneficial in initiating a conversation with your physician.  Patient reimbursement of up to $599 for time and travel is available.

Age Range

Adults, 18 years and older

l

Informed Consent

Able to understand the study purposes and risks

Condition

Leptomeningeal Metastases

Gender

All; Women have negative pregnancy test at screening; Subjects must use effective contraception during study

Additional eligibility criteria may be found on ClinicalTrials.gov

What Can You Do Next?

Participating in a clinical trial is an important decision.  If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Request Information

10 + 1 =